Recent Updates
Recently added Catalysts
CGON Positive Sentiment

REUTERS

Thursday, December 5, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CG Oncology's experimental immunotherapy has shown promising results in treating bladder cancer, particularly in patients who are high-risk and have been exposed to BCG therapy. The company recently reported positive outcomes from its CORE-1008 trial, which evaluates an intravesical combination therapy. CG Oncology is also set to present at upcoming investor conferences.
Price reaction · baseline $35.91 (2024-12-04 close) · hit pre-market · 4 other CGON headline(s) in the window, move may be shared
day 0 close · peak
-6.5%
day 1
-3.7%
day 3
-6.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Experimental immunotherapy shows promise in treating bladder cancer.
  • Positive results reported from CORE-1008 trial.
  • CG Oncology actively participates in research and conferences.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+139%
120-day peak, hindsight
Typical move
6.3%
average across 5 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
CG0070
Phase 2 · Non Muscle Invasive Bladder Cancer

Full Press Release Details

by admin | Dec 5, 2024 | in-the-news | 0 comments
Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer

Recent Posts

• CUA 2026 – BOND-003 Cohort C Podium
• CG Oncology to Present at Upcoming Investor Conferences in June
• SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
• CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
• AUA 2026 – CORE 008 Cohort CX Presentation

Recent Comments

Frequently Asked Questions

What recent results did CG Oncology report?

CG Oncology reported positive results from its CORE-1008 trial evaluating intravesical combination therapy.

What type of cancer is CG Oncology targeting?

CG Oncology is focusing on bladder cancer, particularly in high-risk patients.

Will CG Oncology present at any conferences?

Yes, CG Oncology is scheduled to present at upcoming investor conferences.

What is the CORE-1008 trial about?

The CORE-1008 trial evaluates a combination therapy for patients unresponsive to BCG.

ShareAdd on Google
Tags: CGON Viatris Investor Conferences Healthcare CG Oncology bladder cancer immunotherapy CORE-1008 BCG therapy
Last updated: Dec 5, 2024

Biotech snapshot

Cash runway
$1028M liquidity · $15M/mo burn
~66 mo
Minimal dilution risk
Lead asset
CG0070Phase 2
Non Muscle Invasive Bladder Cancer →

Catalyst track record

+139%
best trade around CGON's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for CGON.

See every catalyst's timing & PoA →